Neil Wallen, MD
Allergy · Bristol, TNNPI 1326043373
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 580 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations.
Across 580 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- CSL Behring$2K
- Sanofi$1K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$2002%
- Food & beverage$11,85698%
- Education$961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 109 | $1,968 |
| CSL Behring | 71 | $1,513 |
| Sanofi | 60 | $1,442 |
| GSK | 72 | $1,372 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $1,135 |
| Regeneron Healthcare Solutions, Inc. | 38 | $1,002 |
| Kaleo, Inc. | 46 | $936 |
| Amgen | 36 | $801 |
| Shire North American Group Inc | 11 | $399 |
| Biocryst US Sales Co., LLC | 12 | $238 |
| Boehringer Ingelheim | 15 | $235 |
| Grifols USA, LLC | 10 | $183 |
| Octapharma USA, Inc. | 6 | $170 |
| Pfizer | 7 | $124 |
| Novartis | 5 | $94 |
| Pharming Healthcare, Inc. | 4 | $86 |
| Teva Pharmaceuticals USA, Inc. | 4 | $85 |
| Hospira, Inc. | 3 | $77 |
| Mylan Specialty L.p. | 4 | $55 |
| Sunovion Pharmaceuticals Inc. | 3 | $45 |
| Optinose US, Inc. | 2 | $38 |
| Merck | 2 | $32 |
| Circassia Inc. | 2 | $23 |
| AbbVie | 1 | $19 |
| Biocryst Pharmaceuticals, Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
How this compares
Too few allergy providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 37 | $149,586 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $67,939 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $44,907 |
| XolairOmalizumab | 15 | $41,671 |
| Spiriva RespimatTiotropium Bromide | 32 | $36,625 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $22,798 |
| Epinephrine | 52 | $15,124 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $13,465 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $11,684 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $8,637 |
| Ipratropium Bromide | 72 | $3,968 |
| Fluticasone Propionate HfaFluticasone Propionate | 12 | $3,837 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 94 | $3,041 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 28 | $2,085 |
| Montelukast Sodium | 140 | $1,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,372 | $79,623107 claims |
| Grifols USA, LLCGamunex-C | $183 | $44,90717 claims |
| Boehringer IngelheimSpiriva Respimat | $235 | $36,62532 claims |
| AstraZenecaSymbicort | $1,968 | $22,79858 claims |
| Hikma Pharmaceuticals USAEpinephrine | $14 | $15,12452 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $85 | $8,63713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Other allergy in Bristol
- David HagamanNashville$446K
- Emily CampbellNashville$6K
- Ryan SullivanSpring Hill$5K
- Leslie NewmanSmyrna$5K
- Chrishana OgilvieGermantown$2K
- Martha ButterfieldSmyrna$2K
- Steve ColeMemphis$1K
- Keegan SmithNashville$978
- Kimberly BergeronBrentwood$532
- Robert OwenBrentwood$494
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.